Clinical pharmacology and dietary supplements: An evolving relationship

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 2, 2010, Pages 235-238

  Gurley, B J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; DIET SUPPLEMENTATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; PRIORITY JOURNAL; SHORT SURVEY; UNITED STATES;

DIETARY SUPPLEMENTS; EPHEDRA; FOOD INDUSTRY; GOVERNMENT REGULATION; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; LEGISLATION, FOOD; PHARMACOLOGY, CLINICAL; UNITED STATES;

EID: 75849121194     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.245     Document Type: Short Survey

References (38)

1. Nahin R.L., Barnes P.M., Stussman B.J., Bloom B. Costs of Complementary and alternative Medicine (CaM) and frequency of Visits to CaM Practitioners: United States 2007. National Health Statistics Reports No. 18 (US Department of Health and Human Services, Hyattsville, MD, 2009).
2. Dietary Supplement Health and Education act (DSHEa), Public Law 103-417, 1994; act 42 U.S.C. 287C-11.
3. Shahrokh, L.E., Lukaszuk, J.M. & Prawitz, A.D. Elderly herbal supplement users less satisfed with medical care than nonusers. J. Am. Diet. Assoc. 105, 1138-1140 (2005).
4. Cohen, P.J. Science, politics, and the regulation of dietary supplements: it's time to repeal DSHEa. Am. J. Law Med. 31, 175-214 (2005).
5. Epstein K. Ephedra: the adventure continues. Washington Post, 23 May 2000.
6. Gurley, B.J., Gardner, S.F. & Hubbard, M.a. Content versus label claims in ephedra-containing dietary supplements. Am. J. Health Syst. Pharm. 57, 963-969 (2000)
7. Haller, C.A. & Benowitz, N.L. adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N. Engl. J. Med. 343, 1833-1838 (2000).
8. Haller, C.a., Jacob, P. & Benowitz, N.L. Short-term metabolic and hemodynamic efects of ephedra and guarana combinations. Clin. Pharmacol. Ther. 77, 560-571 (2005)
9. Dulloo, A.G., Seydoux, J., Girardier, L., Chantre, P. & Vandermander, J. Green tea and thermogenesis: interactions between catechin-polyphenols, cafeine and sympathetic activity. Int. J. Obes. Relat. Metab. Disord. 24, 252-258 (2000).
10. Brown, N.J., Ryder, D. & Branch, R.a. a pharmacodynamic interaction between cafeine and phenylpropanolamine. Clin. Pharmacol. Ther. 50, 363-371 (1991).
11. Young, R., Gabryszuk, M. & Glennon, R.a. (-)Ephedrine and cafeine mutually potentiate one another's amphetamine-like stimulus efects. Pharmacol. Biochem. Behav. 61, 169-173 (1998)
12. New drug status of OTC combination drug products containing cafeine, phenylpropanolamine, and ephedrine. Fed. Regist. 47, 35344-35345 (1982).
13. Gurley, B.J., Gardner, S.F., White, L.M. & Wang, P.L. Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang). Ther. Drug Monit. 20, 439-445 (1998)
14. Haller, C.a., Jacob, P. 3rd & Benowitz, N.L. Enhanced stimulant and metabolic efects of combined ephedrine and cafeine. Clin. Pharmacol. Ther. 75, 259-273 (2004)
15. US Department of Health and Human Services, food and Drug administration. final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed. Regist. 69, 6787-6854 (2004).
16. Nasir, J.M., Durning, S.J., ferguson, M., Barold, H.S. & Haigney, M.C. Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine. Mayo Clin. Proc. 79, 1059-1062 (2004).
17. Bouchard, N.C., Howland, M.A., Greller, H.A., Hofman, R.S. & Nelson, L.S. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin. Proc. 80, 541-545 (2005).
18. Gardiner, P., Graham, R.E., Legedza, a.T., Eisenberg, D.M. & Phillips, R.S. factors associated with dietary supplement use among prescription medication users. Arch. Intern. Med. 166, 1968-1974 (2006).
19. Wold, R.S. et al. Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J. Am. Diet. Assoc. 105, 54-63 (2005).
20. Dürr, D. et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CyP3a4. Clin. Pharmacol. Ther. 68, 598-604 (2000)
21. Roby, C.A., anderson, G.D., Kantor, E., Dryer, D.A. & Burstein, a.H. St John's Wort: efect on CyP3a4 activity. Clin. Pharmacol. Ther. 67, 451-457 (2000).
22. Wang, Z., Gorski, J.C., Hamman, M.a., Huang, S.M., Lesko, L.J. & Hall, S.D. The efects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 70, 317-326 (2001).
23. Ruschitzka, F., Meier, P.J., Turina, M., Lüscher, T.F. & Noll, G. acute heart transplant rejection due to Saint John's wort. Lancet 355, 548-549 (2000).
24. Barone, G.W., Gurley, B.J., Ketel, B.L. & abul-Ezz, S.R. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 71, 239-241 (2001).
25. Moore, L.B. et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. USA 97, 7500-7502 (2000).
26. Gurley, B.J. et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 72, 276-287 (2002).
27. Ioannides, C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32, 451-478 (2002).
28. Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A. & Paxton, J.W. Interactions of herbs with cytochrome P450. Drug Metab. Rev. 35, 35-98 (2003).
29. Van Breemen, R.B., Fong, H.H. & Farnsworth, N.R. The role of quality assurance and standardization in the safety of botanical dietary supplements. Chem. Res. Toxicol. 20, 577-582 (2007).
30. Markowitz, J.S., Von Moltke, L.L. & Donovan, J.L. Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations. Mol. Nutr. Food Res. 52, 747-754 (2008).
31. Smolinske, S.C. Herbal product contamination and toxicity. J. Pharm. Pract. 18, 188-208 (2005)
32. Final rule: current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Fed. Regist. 72, 34751-34958 (2007).
33. Ko, R. Safety of ethnic & imported herbal and dietary supplements. Clin. Toxicol. (Phila). 44, 611-616 (2006).
34. Cole, M.R. Fetrow, C.W. adulteration of dietary supplements. Am. J. Health Syst. Pharm. 60, 1576-1580 (2003).
35. Fleshner, N. et al. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J. Urol. 174, 636-641; discussion 641; quiz 801 (2005).
36. food and Drug administration. Warning on Body Building Products Marketed as Containing Steroids or Steroid-Like Substances (US Department of Health and Human Services, Rockville, MD).
37. food and Drug administration. More Weight Loss Products added to Consumer alert (US Department of Health and Human Services, Rockville, MD).
38. Sampson, W. Studying herbal remedies. N. Engl. J. Med. 353, 337-339 (2005).